98 related articles for article (PubMed ID: 26212264)
21. Anti-hyperglycemic and hypolipidemic effects of Cistanche tubulosa in type 2 diabetic db/db mice.
Xiong WT; Gu L; Wang C; Sun HX; Liu X
J Ethnopharmacol; 2013 Dec; 150(3):935-45. PubMed ID: 24095831
[TBL] [Abstract][Full Text] [Related]
22. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
23. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis.
Mackey RH; Mora S; Bertoni AG; Wassel CL; Carnethon MR; Sibley CT; Goff DC
Diabetes Care; 2015 Apr; 38(4):628-36. PubMed ID: 25592196
[TBL] [Abstract][Full Text] [Related]
25. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
26. Levels of the first-phase insulin secretion deficiency as a predictor for type 2 diabetes onset by using clinical-metabolic models.
Lin JD
Ann Saudi Med; 2015; 35(2):138-45. PubMed ID: 26336020
[TBL] [Abstract][Full Text] [Related]
27. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
28. Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.
Zhao D; Yang LY; Wang XH; Yuan SS; Yu CG; Wang ZW; Lang JN; Feng YM
Cardiovasc Diabetol; 2016 Sep; 15(1):132. PubMed ID: 27620179
[TBL] [Abstract][Full Text] [Related]
29. Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial.
Geohas J; Daly A; Juturu V; Finch M; Komorowski JR
Am J Med Sci; 2007 Mar; 333(3):145-53. PubMed ID: 17496732
[TBL] [Abstract][Full Text] [Related]
30. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
31. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
32. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus.
Frénais R; Nazih H; Ouguerram K; Maugeais C; Zaïr Y; Bard JM; Charbonnel B; Magot T; Krempf M
J Clin Endocrinol Metab; 2001 May; 86(5):1962-7. PubMed ID: 11344192
[TBL] [Abstract][Full Text] [Related]
33. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin.
Chan JL; Abrahamson MJ
Mayo Clin Proc; 2003 Apr; 78(4):459-67. PubMed ID: 12683698
[TBL] [Abstract][Full Text] [Related]
35. GPR40: a therapeutic target for mediating insulin secretion (review).
Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
[TBL] [Abstract][Full Text] [Related]
36. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
37. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
38. [Autoimmune insulitis in patients with type 2 diabetes mellitus A randomized clinical trial in hospitalized patients].
Martinka E; Rončáková M; Mišániková M; Davani A
Vnitr Lek; 2016; 62(7-8):521-33. PubMed ID: 27627073
[TBL] [Abstract][Full Text] [Related]
39. Reverse cholesterol transport in type 2 diabetes mellitus.
Tan KC
Diabetes Obes Metab; 2009 Jun; 11(6):534-43. PubMed ID: 19175378
[TBL] [Abstract][Full Text] [Related]
40. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
